At Week 24, researchers found 67% of patients receiving 4 mg baricitinib achieved resolution of SLEDAI-2K arthritis or rash. The safety profile of baricitinib in patients with active SLE receiving standard of care treatment was consistent with previously published findings. The 4 mg treatment group experienced a single episode of deep-vein thrombosis. Baricitinib treatment also resulted in modest dose-associated decreases in hemoglobin neutrophil and triglyceride concentrations, as well as increases in platelet counts, concentrations of creatine phosphokinase, HDL cholesterol and total cholesterol.
You Might Also Like
Also By This Author
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
- Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Jul 21;392(10143):222–231. doi: 10.1016/S0140-6736(18)31363-1.